NasdaqGM:WVEPharmaceuticals
Wave Life Sciences (WVE) Deepens Obesity Bet With WVE-007 Focus – Is Its Platform Strategy Evolving?
Wave Life Sciences recently outlined its 2026 priorities at the 44th Annual J.P. Morgan Healthcare Conference, emphasizing accelerated development of obesity candidate WVE-007, expansion of its RNA editing pipeline, and upcoming trials and regulatory filings across obesity, liver disease, and genetic disorders.
A key highlight for investors was early WVE-007 data suggesting fat loss on par with GLP-1 therapies while preserving muscle, alongside planned multidose and add-on incretin trials...